The charts of 31 hospitalized children and adolescents (ages 9\p=n-\18 years) with major mood disorders were retrospectively reviewed to examine the efficacy and side effects of treatment with fluoxetine. After treatment for a mean duration of 35 
INTRODUCTION
Since its introduction in January 1988, fluoxetine has become one of the most widely prescribed antidepressants in America. While there are comprehensive data in the adult literature on fluoxetine for the indications of major depressive (MDD) and obsessive-compulsive disorders (Fontaine and Chouinard 1986, Jenike et al. 1989 , Leonard and Rapoport 1990 , March et al. 1989 , Murphy and Pigott 1990 , Nierenberg and Amsterdam 1990 , Turner et al. 1985 , research in child and adolescent patients has been sparse. Simeon et al. (1990) , in a double-blind placebo-controlled study, administered fluoxetine up to 60 mg/day to 40 inpatient and outpatient adolescents with MDD (ages 13-18 years). Of the 30 patients who completed the study, there was a statistically significant difference between fluoxetine and placebo only with respect to anxiety. The most frequently reported side effects included headache (43%), tremor (29%), insomnia (24%), rhinitis (24%), vomiting (14%), and weight loss (14%). No relationship was identified between the dose of fluoxetine and the plasma level.
METHODS
The charts of 31 The overall effectiveness as well as the therapeutic benefit of fluoxetine were recorded on the Clinical Global Impression Scale (CGI). This scale has three subscales: (1) "the severity of the illness" is scored from 1 (normal, not ill) to 7 (among the most extremely ill patients) and was determined from the patient's initial presentation at admission; (2) the "global improvement scale" is a measure of how the patient did during the course of therapy on the drug, and it is scored from 1 (very much improved) to 7 (very much worse); (3) the "efficacy index" is a 4 x 4 matrix table which assesses the therapeutic effect of the medication (on the y axis) on side effects (on the x axis). Sixteen potential outcomes are possible, with each number between 1 and 16 designating a specific side-effect-to-benefit ratio (though not in consensual order). The therapeutic effect is ranked from "marked improvement" to "unchanged," while the side effects run from "none" to "outweighs any positive effect." (0.83,0.79, and 0 .89 between raters 1-2, 1-3, and 2-3, respectively).
RESULTS

Efficacy
Most (74%) of the sample showed some improvement; 54% had "much" to "very much" improvement, 43% had "minimal" improvement or no change, and 3% had worsening.
After treatment with fluoxetine, the results of the CGI showed several significant findings. The mean "global improvement score" was 2.7 ±1.1 (median score 2.3, with a range of 1.3-6.0), which suggests that there was "minimal" to "much" improvement (see Fig. 1 ). Females (3.1 ± 1.3) tended to show more improvements than males (2.4 ± 0.9) (Mann-Whitney,/? < 0.09). The mean "efficacy index" was 7.2 ± 3.6 (median rating of 6, with a range of 1.3-15) . This corresponds to a risk/benefit ratio that suggests that the side effects of fluoxetine "do not significantly interfere with the patients' functioning". The mean "severity index" was 4.8 ± 0.7 (median of 5, with a range of 2-6), suggesting that most patients were "markedly ill." There were no effects of age on any of the three rating scales previously mentioned.
Side effects
The mean onset of side effects was within 12 ± 11 days. The most common side effects were hypomania-like symptoms (23%), irritability (19%), insomnia (13%), and gastrointestinal upset (13%) (see Table 1 ). Twenty-eight percent of the patients on fluoxetine had the medication discontinued. The three most common reasons for discontinuation were irritability (12%), hypomania-like symptoms (7%), and lack of improvement (7%). In the latter group, the duration of the trials were 27, 29, and 49 days.
There were no EKG changes after the initiation of the medication. The mean systolic and diastolic blood pressure prior to starting fluoxetine was 108 ± 11 and 65 ± 9 mmHg, respectively. The mean systolic and diastolic pressure while on fluoxetine was 104 ± 12 mmHg and 62 ± 9 mmHg, respectively. The changes in both systolic and diastolic pressures were not significant. While posttreatment weight recordings were only obtained in 18 of the patients, there were no significant changes in weight prior to starting the medication and at the time of discharge. CBC with differential and chemistry panels were found to be within the normal range. None of the patients had increased suicidal or parasuicidal ideation.
Concurrent medications and comorbid diagnoses
Twelve (35%) of the depressed patients required the concurrent use of another drug started after fluoxetine. Eight (25%) patients were treated with lithium (5 with MDD, 3 with depressive bipolar disorder), 3 (10%) patients with MDD received neuroleptics, and 1 (2%) patient with depressive bipolar disorder was taking methylphenidate. There were no significant differences in the therapeutic response and side effects between those taking fluoxetine alone or in combination with other medications. 
DISCUSSION
Interest in fluoxetine has increased, partially because its therapeutic efficacy in adults has been shown to rival that of conventional tricyclic antidepressants (Jenike et al. 1990, Stark and Hardison 1985) and partially because fluoxetine does not have the same overdose potential and great number of side effects. The risk of a lethal intake has always been a major detractor when tricyclic antidepressants are used in adolescents. The confidence in prescribing fluoxetine has led to its increased use in younger children.
The use of fluoxetine, in our sample, led to 74% of patients having some improvement, of which 52% had much to very much improvement (see Fig. 1 ). The response rate is consistent with other placebo response rates in other studies of depression in children and adolescents. In this study, 59% of the patients had one adverse effect, and half of these had multiple symptoms. However, in the majority of cases, the side effects did not interfere with the patients' functioning, as reflected in the efficacy index subscale of the CGI.
Irritability was the most common reason for discontinuation of fluoxetine. In two of the cases, a dose relationship was noted: irritability worsened as the dose was increased, and then decreased as the dose was dropped. The irritability had a quality of a grinding anger with short temper and increasing oppositionalism.
Other symptoms that were commonly cited in the charts included a constant sense of silliness, increased activity, poor sleep, increased energy, an increase in the stream of thoughts (racing thoughts), and socially intrusive and obnoxious behavior. These hypomania-like effects may have been more prevalent had the duration of the trials been longer. Some of the patients with major depression who had this symptom may, in fact, tum out to be bipolar.
The hypomania-like symptoms in our study were similar to the "behavioral activation" as described by Riddle et al. (1990) . In the studies done by Riddle's group, the parents and teachers described the children as "revved up," "hyper," and "super energized." Jerome (1991) described a single case of fluoxetine-induced "reactive hypomania" which had the added quality of "grandiosity. " Achamallah and Decker ( 1991 ) reported a single case of mania induced by fluoxetine in a 15-year-old boy five days after medication was started. Since the structure of fluoxetine is very similar to an amphetamine (Schmidt et al. 1988) , it may be that the "activation" triggered by fluoxetine is a mild stimulant-like euphoria aroused by the medication (Rapoport et al. 1980) . In this study, fluoxetine was found to be a safe drug. While this study does not have data on overdoses, the adult literature suggests that risks are minimal even with large overdoses (Wernicke 1985) . Riddle et al. (1988) reported a patient, after ingesting 1.88 grams of fluoxetine, who experienced a grand mal seizure, nausea, dizziness, headache, and EKG changes. In our study, EKG findings (both before the medication was begun and after peak dosing) did not change, even when the dose was at 80 mg per day. Also blood pressure and weight did not change. Teicher et al. (1990) reported the emergence of intense suicidal preoccupation 2-7 weeks after fluoxetine treatment in 6 patients who had all been previously treated with MAOIs. King et al. (1991) described the emergence of self-destructive behavior in 6 obsessive-compulsive patients, aged 10-17. However, as both above studies noted, it was difficult to separate the course of an illness, which may manifest suicidal ideation, from an iatrogenic effect of a medication. None of the patients in our study had increased suicidal ideation. It may be, however, that the length of time the patients were treated with medication did not allow for this effect to be exposed (Schweizer et al. 1990) , and the small number in the sample may have been insufficient to uncover the symptom. Hersh et al. ( 1991 ) reported a case of transient psychosis but recognized that the history of head trauma and abnormal EEG may have been mitigating factors that contributed to the emergence of this symptom. Other side effects that were noted included insomnia (13%), fatigue (10%), headache (2%), nausea (2%), and tremor (2%).
Increased maximum doses and larger samples may have uncovered greater problems, but the four patients who received doses larger than 40 mg showed no increased benefit or side effects. The present dosing schedule is the same as the regimen used in adults (Altamura et al. 1988 , Wemicke et al. 1989 ). More study is required to determine the pharmacokinetics in children and adolescents, and better dosing schedules could evolve from such work.
This study was undertaken as a preamble to further investigations into fluoxetine in children and adolescents. The greatest limitation of this study was that it was a retrospective analysis. The study could be enhanced by having standardized lists of side effects, formal treatment outcome measures, and a placebocontrolled, double-blind, prospective design. This would be the more objective way to determine the effectiveness of this drug as well as to establish clear guidelines to assess the severity of the illness process and the adverse symptoms. It is highly conceivable that the use of fluoxetine will continue to spread, which will increase the urgency to do these tasks.
